Published in Hum Pathol on January 20, 2009
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer (2010) 0.84
Common variation in Nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2012) 0.80
Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors. BMC Cancer (2012) 0.77
The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol (2015) 0.77
Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. J Clin Endocrinol Metab (2016) 0.76
Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS One (2015) 0.76
The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro. Vet Comp Oncol (2013) 0.75
High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq. PLoS One (2015) 0.75
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. Oncotarget (2016) 0.75
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46
Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene (2002) 4.20
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res (2006) 2.73
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res (2006) 2.34
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res (2007) 2.11
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Angiogenesis and ovarian cancer. Clin Transl Oncol (2009) 2.09
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res (2004) 2.04
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol (2002) 1.80
Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene (2003) 1.74
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer (2010) 1.73
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol (2010) 1.63
The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc (2009) 1.60
Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study. Diagn Mol Pathol (2012) 1.56
The nature of halogen...halogen interactions: a model derived from experimental charge-density analysis. Angew Chem Int Ed Engl (2009) 1.56
KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One (2009) 1.50
Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res (2008) 1.48
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology (2009) 1.47
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene (2002) 1.46
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol (2011) 1.46
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis (2005) 1.44
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene (2004) 1.39
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer (2008) 1.39
An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer. BMC Cancer (2010) 1.34
Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem (2006) 1.34
Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques (2010) 1.31
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med (2011) 1.28
Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol (2006) 1.27
Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res (2006) 1.22
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.21
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
Can this patient be discharged home? Factors associated with at-home death among patients with cancer. J Clin Oncol (2011) 1.20
Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol (2008) 1.19
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19
Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol (2015) 1.14
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol (2005) 1.14
Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat (2006) 1.13
Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control (2004) 1.13
Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst (2011) 1.12
Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat (2006) 1.12
Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res (2003) 1.11
MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One (2012) 1.10
Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol (2009) 1.08
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer (2010) 1.07
Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications. Am J Surg Pathol (2012) 1.07
Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients. J Trauma (2010) 1.06
TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol (2008) 1.06
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol (2013) 1.05
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol (2005) 1.05
Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol (2003) 1.04
Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol (2006) 1.04
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology (2009) 1.04
Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol (2004) 1.03
Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol (2003) 1.02